Want to see SE:ESSITY.B full AI Analyst Report?
Top Page
Essity AB
(ESSITY.B)
Select Model
Select Model
Rating:69Neutral
Price Target:
kr303.00
▲(8.14% Upside)
Action:Reiterated
Date:10/23/26
The score is driven primarily by financially sound fundamentals with improved leverage but uneven growth and cash-flow consistency. Technicals are supportive with the stock in an uptrend, though momentum is getting stretched. Valuation is fair with a supportive dividend, while the latest earnings call adds caution due to expected Q4 cost inflation and recent margin pressure.
Positive Factors
Personal Care Market Share
Share gains across branded Incontinence Care, Feminine Care and other Personal Care categories indicate stronger consumer and channel positioning. Because the gains translated into higher volume and sales, they support durable growth potential and better utilization of Essity’s established brands.
Negative Factors
Weak Organic Growth
Negative organic growth shows that reported sales expansion currently depends on acquisitions and currency rather than broad-based underlying demand. This limits the durability of top-line growth and leaves Essity reliant on successful integration, pricing and recovery in weaker categories.
Read all positive and negative factors
Positive Factors
Negative Factors
Personal Care Market Share
Share gains across branded Incontinence Care, Feminine Care and other Personal Care categories indicate stronger consumer and channel positioning. Because the gains translated into higher volume and sales, they support durable growth potential and better utilization of Essity’s established brands.
Read all positive factors
Essity AB (ESSITY.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr185.92B
Dividend Yield3.19%
Average Volume (3M)1.35M
Price to Earnings (P/E)16.8
Beta (1Y)0.42
Revenue Growth-1.84%
EPS Growth-8.27%
CountrySE
Employees36,000
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)16.33
Shares Outstanding626,982,100
10 Day Avg. Volume1,519,157
30 Day Avg. Volume1,349,972
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)2.13
Price to Sales (P/S)1.32
P/FCF Ratio21.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr260.50Price Target Upside-7.03% Downside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)18.54
Revenue Forecast (FY)kr141.63B
Essity AB Business Overview & Revenue Model
Company Description
Essity AB (publ) is a global manufacturer and distributor of personal care and wellness goods, along with related services. Its portfolio encompasses medical and healthcare items such as incontinence management solutions, wound care treatments, co...
How the Company Makes Money
Essity makes money primarily by selling hygiene and health products across multiple categories and channels. Its key revenue streams come from: (1) Consumer products sold through retailers and e-commerce, including personal care (e.g., incontinenc...
Essity AB Earnings Call Summary
Earnings Call Date:Oct 22, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Jan 21, 2027
Earnings Call Sentiment Neutral
The call presented a resilient but mixed quarter. Positive elements included stable group volumes, reported sales growth, market-share gains in Personal Care, progress in Feminine Care acquisitions, strong cash flow, a strong balance sheet, cost-saving execution and continued innovation. These were offset by negative organic sales growth, declines in Consumer Tissue, Baby Care and total Professional Hygiene volumes, substantial COGS inflation, margin contraction, elevated restructuring charges and expectations for further Q4 cost increases. Overall, the positive operational and strategic progress was balanced by significant cost and market pressures.Positive Updates
Resilient Overall Performance and Stable Group Volumes
Management characterized the third quarter as resilient, with stable performance in a challenging market. Group volumes were stable overall, supported by volume-led growth in higher-margin categories and segments including incontinence care, Feminine Care, Wound Care, health care and premium Professional Hygiene products.
Negative Updates
Organic Sales Growth Was Slightly Negative
Although reported net sales increased 4.1%, organic sales growth was slightly negative at minus 0.3%.
Read all updates
Q3-2026 Updates
Positive
Negative
Resilient Overall Performance and Stable Group Volumes
Management characterized the third quarter as resilient, with stable performance in a challenging market. Group volumes were stable overall, supported by volume-led growth in higher-margin categories and segments including incontinence care, Feminine Care, Wound Care, health care and premium Professional Hygiene products.
Read all positive updates
Company Guidance
For Q4, Essity expects “significantly higher COGS” year-on-year and sequentially, with a “fairly high number” versus Q3; SG&A excluding A&P is expected to be “roughly on the same level or actually even slightly lower” than Q4 of 2025 and sequentially, Q4 savings are expected to be “even bigger” than the “roughly about SEK 150 million or slightly more than SEK 150 million” delivered in Q3, and the cost-saving program is expected to deliver “in line or more than” promised, while A&P is expected to be “slightly higher” than Q3. Price increases will continue, with Consumer Tissue taking “roughly 2 quarters to compensate,” and the 1.2% volume impact from the Latin American factory footprint optimization is expected to remain in Q4, Q1 and Q2 of 2027; annual savings from that initiative are “roughly about SEK 150 million, SEK 160 million or $70 million.” The Feminine Care transaction in Brazil is expected to close by Q2 '27, A&P ambition remains “5.3%, 5.7% of sales,” Health & Medical volume growth is anticipated to return, and the tariff impact was described as “approximately about 60 basis points” for Professional Hygiene and “[ 20%, 30% ] basis points” for the group as a whole.Essity AB Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
67
Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 138.99B | 138.49B | 145.55B | 147.15B | 156.17B | 121.87B |
| Gross Profit | 45.04B | 46.12B | 47.13B | 45.13B | 37.23B | 35.09B |
| EBITDA | 24.43B | 25.74B | 26.14B | 21.77B | 15.44B | 19.40B |
| Net Income | 11.12B | 12.66B | 20.89B | 9.55B | 5.57B | 8.62B |
Balance Sheet | ||||||
| Total Assets | 185.00B | 167.12B | 185.28B | 202.99B | 210.60B | 175.05B |
| Cash, Cash Equivalents and Short-Term Investments | 6.56B | 9.75B | 15.62B | 6.94B | 4.50B | 4.09B |
| Total Debt | 39.24B | 37.92B | 43.78B | 60.98B | 71.52B | 58.19B |
| Total Liabilities | 87.36B | 81.08B | 96.54B | 123.59B | 134.04B | 106.54B |
| Stockholders Equity | 97.20B | 85.63B | 88.31B | 70.85B | 67.35B | 59.87B |
Cash Flow | ||||||
| Free Cash Flow | 11.92B | 8.37B | 9.40B | 14.68B | 7.44B | 7.31B |
| Operating Cash Flow | 18.71B | 15.46B | 16.80B | 21.57B | 12.87B | 14.67B |
| Investing Cash Flow | -8.94B | -3.22B | 9.41B | -7.11B | -14.50B | -12.13B |
| Financing Cash Flow | -10.66B | -14.40B | -22.34B | -11.55B | 1.81B | -3.81B |
Essity AB Technical Analysis
Positive
280.20
Price Trends
268.81
Positive
272.11
Positive
263.41
Positive
Market Momentum
2.98
Negative
60.93
Neutral
35.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ESSITY.B, the sentiment is Positive. The current price of 280.2 is above the 20-day moving average (MA) of 268.93, above the 50-day MA of 268.81, and above the 200-day MA of 263.41, indicating a bullish trend. The MACD of 2.98 indicates Negative momentum. The RSI at 60.93 is Neutral, neither overbought nor oversold. The STOCH value of 35.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ESSITY.B.
Essity AB Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
85 Outperform | kr5.50B | 12.07 | 48.04% | 4.36% | 32.85% | 101.50% | |
69 Neutral | kr185.92B | 16.81 | 12.25% | 3.19% | -1.84% | -8.27% | |
65 Neutral | kr1.38B | 8.33 | 5.43% | 2.32% | -1.42% | ― | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
58 Neutral | kr115.85M | 14.72 | ― | 1.34% | 3.50% | 58.41% | |
52 Neutral | kr2.57B | -5.53 | -9.80% | ― | 3.05% | -1130.58% | |
48 Neutral | kr3.14B | 24.06 | 3.91% | 7.47% | -2.46% | -59.94% |
* Consumer Defensive Sector Average
SE:ESSITY.B
Essity AB
274.50
21.09
8.32%
SE:ZZ.B
Zinzino AB
137.50
26.19
23.53%
SE:MSON.B
Midsona AB Class B
9.50
1.42
17.62%
SE:DUNI
Duni AB
66.90
-33.73
-33.52%
SE:HUMBLE
Humble Group AB
5.68
-2.43
-29.96%
SE:NNH
New Nordic Healthbrands AB
18.70
-6.00
-24.28%
Essity AB Corporate Events
Essity balances softer margins with strong cash flow and Brazil feminine care acquisition
Oct 22, 2026
Essity reported third‑quarter 2026 net sales up 4.1% to SEK 36,060m, but organic sales slipped 0.3% and profitability softened, with the EBITA margin excluding items affecting comparability down to 13.1% and earnings per share declining year...
Essity Expands Treasury Stock Through Ongoing SEK 3bn Share Buyback
Oct 19, 2026
Essity has continued executing its share buyback program, repurchasing 259,436 Class B shares on Nasdaq Stockholm during week 42 of 2026 for a total consideration of about SEK 69.9m, at a weighted average price of SEK 269.42 per share. The transac...
Essity Advances SEK 3bn Share Buyback, Boosting Treasury Holdings
Oct 12, 2026
Essity has continued executing its SEK 3bn share buyback program, repurchasing 423,823 Class B shares on Nasdaq Stockholm during the week of October 5–9, 2026, at a total value of about SEK 110.5m. The transactions, carried out by BofA Secur...
Essity accelerates share buybacks as treasury holding rises
Oct 5, 2026
Essity AB has continued to execute its previously announced SEK 3bn share buyback program, repurchasing 425,114 Class B shares on Nasdaq Stockholm between September 28 and October 2, 2026. The transactions, handled by BofA Securities Europe SA, br...
Essity updates share structure after Class A to Class B conversion
Sep 30, 2026
Essity AB has reported a change in its share capital structure following shareholder requests to convert Class A shares into Class B shares, a mechanism provided for in the company’s articles of association. Such conversions reduce the total...
Essity Advances SEK 3bn Share Buyback, Lifts Treasury Share Holdings
Sep 28, 2026
Essity has continued executing its SEK 3bn share buyback program, repurchasing 402,677 Class B shares on Nasdaq Stockholm during the week of September 21–25, 2026, at a weighted average price of SEK 262.30 and a total value of about SEK 105....
Essity appoints Nomination Committee ahead of 2027 AGM
Sep 23, 2026
Essity has appointed its Nomination Committee for the 2027 Annual General Meeting in line with instructions adopted in 2020, assigning seats to representatives of its four largest shareholders and the company’s chairman. The committee, led b...
Essity Sets Date for Q3 2026 Interim Report Presentation
Sep 22, 2026
Essity AB, the Stockholm-based hygiene and health group listed on Nasdaq Stockholm, operates globally with a portfolio of consumer and professional brands including TENA, Tork, Libero, Libresse, Modibodi and Tempo. Its products and services reach ...
Essity Advances SEK 3bn Share Buyback Program
Sep 21, 2026
Essity has continued executing its SEK 3bn share buyback program, repurchasing 397,967 Class B shares on Nasdaq Stockholm during week 38 of 2026 for a total of about SEK 105m. The program, financed from cash flow after ordinary dividends and inten...
Essity CFO Fredrik Rystedt to Retire in 2027, Succession Process Underway
Sep 21, 2026
Essity has announced that its Chief Financial Officer and Executive Vice President, Fredrik Rystedt, plans to retire during 2027 after more than nine years in the role, prompting the immediate start of a search for his successor. Rystedt will rema...
Essity Advances SEK 3bn Share Buyback Program With New Class B Repurchases
Sep 14, 2026
Essity has continued executing its previously announced SEK 3bn share buyback program, repurchasing 362,503 Class B shares on Nasdaq Stockholm during week 37 of 2026 for a total value of about SEK 96.1m. The transactions, carried out by BofA Secur...
Essity Advances SEK 3bn Share Buyback, Boosts Treasury Holdings
Sep 7, 2026
Essity AB has continued to execute its previously announced SEK 3bn share buyback program, repurchasing 273,715 Class B shares on Nasdaq Stockholm between August 31 and September 4, 2026, at a total value of about SEK 75.6m. The program, run withi...
Essity Expands Share Buyback Program With Further Class B Repurchases
Aug 31, 2026
Essity has repurchased 267,157 of its own Class B shares on Nasdaq Stockholm during week 35 of 2026 as part of a previously announced SEK 3bn buyback program running until the 2027 AGM. The transactions, executed by BofA Securities Europe, were fi...
Essity Updates Share Class Conversion and Voting Structure
Aug 31, 2026
Essity AB, a global hygiene and health company headquartered in Stockholm and listed on Nasdaq Stockholm, supplies tissue, incontinence, baby and feminine hygiene products and related health solutions under brands including TENA, Tork, Libero, Lib...
Essity Advances SEK 3bn Share Buyback, Strengthens Capital Allocation Strategy
Aug 24, 2026
Essity has continued to execute its previously announced SEK 3bn share buyback program, repurchasing 282,790 Class B shares on Nasdaq Stockholm during week 34, 2026, at a weighted average price of SEK 271.40 and a total value of about SEK 76.8m. T...
Essity Buys Kenvue’s Brazilian Feminine Care Unit to Bolster Latin American Lead
Aug 19, 2026
Essity has agreed to acquire Kenvue’s feminine care business in Brazil, including the market-leading Carefree, Sempre Livre and o.b. brands, for USD 284m on a cash- and debt-free basis. The deal, structured as an asset purchase that also cov...
Essity Advances SEK 3bn Share Buyback With New Week of Repurchases
Aug 17, 2026
Essity has continued executing its share buyback strategy, repurchasing 275,953 Class B shares on Nasdaq Stockholm during the week of August 10–14, 2026, as part of a SEK 3bn program running until the 2027 annual meeting. The company now hol...
Essity Steps Up Share Buybacks as Part of SEK 3bn Capital Return Plan
Aug 10, 2026
Essity has continued to execute on its previously announced SEK 3bn share buyback program, repurchasing 277,688 Class B shares on Nasdaq Stockholm during the week of August 3–7, 2026. The transactions, carried out by BofA Securities Europe o...
Essity Steps Up Share Buybacks as Part of SEK 3bn Capital Return Program
Aug 3, 2026
Essity has continued executing its previously announced SEK 3bn share buyback program, repurchasing 280,884 Class B shares on Nasdaq Stockholm during the week of July 27–31, 2026, at a weighted average price of SEK 279.12. The transactions, ...
Essity Adjusts Voting Structure Through Share Class Conversion
Jul 31, 2026
Essity AB has announced a shareholder-driven conversion of 1,087,417 Class A shares into Class B shares during July, in line with the company’s articles of association that permit such changes. Following the conversion, the total number of v...
Essity Ramps Up Share Buybacks as Part of SEK 3bn Capital Return Program
Jul 27, 2026
Essity has continued executing its previously announced SEK 3bn share buyback program, repurchasing 280,871 Class B shares on Nasdaq Stockholm during week 30 of 2026 at a total value of about SEK 78m. The company has now acquired 3,143,815 shares ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.